drugset / Trial / NCT02639637
Effect of DPP4 Inhibition on Vasoconstriction
RandomizedCrossoverQuadruple-blindBasic science
Summary
The purpose of this study is to understand how dipeptidyl peptidase IV (DPP4) inhibition in diabetics affects hemodynamic parameters and sympathetic activation in the setting of increasing concentrations of neuropeptide Y, an endogenous peptide. The central hypothesis is that DPP4 inhibition decreases degradation of neuropeptide Y, resulting in increased vasoconstriction and sympathetic activation.
Timeline
- Start
- 2015-12
- Primary completion
- 2017-06
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ENALAPRILAT ANHYDROUS | Small molecule | 0.33 unknown | Other |
| Subject | Neuropeptide Y | Peptide | 0.1 unknown | Other |
| Subject | Neuropeptide Y | Peptide | 0.3 unknown | Other |
| Subject | Neuropeptide Y | Peptide | 1 unknown | Other |
| Subject | Neuropeptide Y | Peptide | 3 unknown | Other |
| Subject | Sitagliptin | Small molecule | 100 mg | — |
| Comparator | Valsartan | Small molecule | 160 mg | — |